triple-site biventricular pacing with peri-operative echo guidance
Deviceplacement of the third lead by peri-operative echo guidance.
NCT Number: NCT02350842
Cardiac resynchronization is a recommended therapy for patients with advanced heart failure, under optimized medical treatment with reduced left ventricular ejection fraction and prolonged QRS, nevertheless, still 30% of the population do not respond to standard biventricular implantation.
Non-response can be explained by a combination of factors including sub-optimal patient selection, placement of the pacing lead over a zone of slow conduction, insufficient correction of mechanical dyssynchrony including sub-optimal lead implantation. Few data distinguish true non-responders from patients in which effective resynchronization was not delivered through standard biventricular implantation.
Triple-site cardiac resynchronization pacing (stimulation at three ventricular sites) has been proposed to improve synchrony and thus the response rate in (Cardiac Resynchronisation Therapy) CRT recipients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
CHRU Hopital Sud, Amiens, France
The frequent failure of CRT in non-Left Bundle Branch Block (non-LBBB) patients is suspected to be due to more complex and heterogeneous forms of electrical/mechanical dyssynchronies needing more complex and individualized pacing configurations to be corrected.
Acute studies during implant show that standard biventricular pacing provides optimal mechanical improvement only in a minority of patients. In a peri-operative echo-guided leads placement procedure most of non-improved patients could be successfully mechanically resynchronized. A significant number of patients required optimized placement of right ventricular (RV) lead and/or triple-site configurations.
These studies led to the hypothesis that more complex and individualized pacing configurations (Triple-site biventricular) might increase the number of responders to CRT.
To assess this hypothesis, this study will be conducted in Class II-ambulatory IV patients indicated for CRT with wide QRS (≥ 140 ms) and non-LBBB. Patients will be randomized in a 1:1 configuration:
The objective of the optimization process is to improve LV efficiency and to decrease the left pre-ejection interval (LPEI, defined as the time interval between the onset of QRS and the onset of LV ejection) as much as possible compared with a standard biventricular configuration by moving a second right ventricular lead at different locations.
LPEI is simple to measure, with good inter- and intra-observer reproducibility and its utility has previously been strongly suggested.
Reduction in LPEI results in decreased duration of ventricular systole and is associated with improved LV filling and reduced interventricular delay.
The primary objective of this study is to demonstrate that individually optimized, triple-site biventricular pacing is superior to standard biventricular pacing in reverse ventricular modeling as demonstrated by Echo Left Ventricle End-Systolic Volume (LVESV) at 1 year in patients with non-LBBB morphology without increasing the risk of serious procedure and/or device related adverse events at 30 days.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
placement of the third lead by peri-operative echo guidance.
standard biventricular pacing without optimization by echo guidance
Time frame: 12 months
The efficacy endpoint for this study is the change in LVESV at twelve months post-implant between individually optimized, triple-site biventricular pacing and standard biventricular pacing.
LVESV is a standard marker of CRT effectiveness1. Echocardiographic data collected at twelve months follow-up will document the evolution of LVESV as compared to baseline in order to assess reverse ventricular remodeling.
The safety endpoint for this study is the rate of all serious procedure and/or device related events reported at thirty days post-implant.
Time frame: 6 and 12 months
A safety assessment will be performed, including all reported events collected for all enrolled patients.
Time frame: 6 and 12 months
Change in LV volumes and LV ejection fraction will be evaluated as part of reverse remodeling response, based on echocardiographic measurements:
Time frame: 6 and 12 months
A patient's clinical status will be evaluated considering:
Time frame: 1, 6 and 12 months
A safety assessment will be performed, including all reported events collected for all enrolled patients.
MicroPort CRM
Industry
Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)
Acronym: TRIUMPH-CRT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05806606
Behavior, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06847438
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07721909
Cardiovascular Diseases, Heart Diseases
Muscat, Oman
View Trial Details